HC Wainwright raises target for Mirum Pharmaceuticals stock

Published on 10/05/2026 at 04:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AZURE-1 delivered 56.00 percent response on September 28, 2026. Mirum Pharmaceuticals stock was last at EUR 77.54 on September 23 after EUR 78.18.

MIRM, US6047491013, Illustration mit AI erstellt.

HC Wainwright raised its price target for Mirum Pharmaceuticals stock from USD 140.00 to USD 195.00 while maintaining a Buy rating, according to MarketBeat on September 28, 2026. The move followed clinical and regulatory milestones that materially expanded Mirum's commercial narrative.

AZURE-1 clears its endpoint

Mirum announced on September 28, 2026 that brelovitug met the Phase 3 AZURE-1 primary endpoint at Week 24. The company's investor release shows combined virologic response and alanine aminotransferase normalization in 56.00 percent of patients receiving 300 milligrams weekly and 45.00 percent receiving 900 milligrams every four weeks, compared with 0.00 percent in the delayed-treatment arm, according to Mirum Pharmaceuticals.

The 153-patient study therefore produced a 56.00 percentage-point gap between the weekly dose and delayed treatment. Mirum said it expects topline results from the second pivotal AZURE-4 study in the fourth quarter of 2026 and plans a Biologics License Application submission in the first half of 2027, according to the same September 28 release.

Revenue grows while losses persist

The commercial base is expanding, but profitability remains a counterweight. In the second quarter of 2026, revenue reached USD 176.24 million, up 37.90 percent from the prior-year quarter, while the loss was USD 1.06 per share versus a USD 0.74 consensus loss, according to MarketBeat. Revenue exceeded the USD 166.33 million consensus estimate by USD 9.91 million, while the loss per share was USD 0.32 wider than expected.

Mirum also received U.S. Food and Drug Administration approval for Atebrioz in patients aged 12 years and older with fibrodysplasia ossificans progressiva on September 25, 2026. Reuters reported that Mirum expects to launch the once-daily drug in October, with pricing to be announced at launch.

Stock context and valuation

The substitute German quote was last at EUR 77.54 on September 23, 2026, after EUR 78.18. On Nasdaq, Mirum was quoted at USD 82.93 on October 2, 2026, with a USD 63.23 to USD 130.00 52-week range and a market capitalization of USD 5.1 billion.

The target increase gives analysts a higher benchmark while the AZURE-1 data add a measurable development milestone. For investors, the central test is whether the second Phase 3 study can convert the clinical response into a regulatory filing and commercial launch.